APPLICATIONS AND SAFETY OF TESTOSTERONE CREAMS: A SYSTEMATIC REVIEW OF TOPICAL FORMULATIONS, CLINICAL EFFICACY, AND POTENTIAL RISKS
DOI:
https://doi.org/10.56238/revgeov17n3-013Keywords:
Topical Testosterone, Testosterone Cream, Hormone Therapy, Androgen Replacement, Skin SafetyAbstract
Testosterone creams and gels have been widely used in clinical practice for hormone replacement and for use without formal clinical indication, mainly among middle-aged and elderly men. This study aims to systematically review the evidence on the composition, mechanisms of action, efficacy, safety, and risks associated with the use of topical testosterone formulations, including creams, gels, ointments, and transdermal patches. Studies indexed in PubMed, Scopus, and SciELO databases between 2010 and 2025 were included. Comparative analysis shows that creams exhibit variable absorption depending on the area applied, the vehicle, and the contact time, while gels offer more stable bioavailability, and transdermal patches maintain continuous release. Although effective in raising serum testosterone levels, these products can cause adverse events, including acne, gynecomastia, alopecia, and possible stimulation of prostate or breast cells. It is concluded that, even with topical use, the systemic risk is significant, and they should be prescribed under rigorous medical evaluation.
Downloads
References
ANVISA – Agência Nacional de Vigilância Sanitária. RDC nº 784/2023 – Regulamento técnico sobre substâncias sujeitas a controle especial. Brasília: ANVISA, 2023.
AUA – American Urological Association. Testosterone Deficiency Guideline. Arlington: AUA, 2022.
BHASIN, S. et al. Testosterone therapy in men with hypogonadism: an Endocrine Society guideline. Journal of Clinical Endocrinology & Metabolism, v. 103, n. 5, p. 1715-1744, 2018. DOI: 10.1210/jc.2018-00229.
BMC WOMEN’S HEALTH. Topical testosterone therapy and aromatase suppression in postmenopausal women with breast cancer. BMC Women’s Health, 2024. DOI: 10.1186/s12905-024-02037-x.
CORONA, G. et al. Testosterone supplementation and body composition: results from a systematic review and meta-analysis. European Journal of Endocrinology, v. 188, n. 4, p. 467-482, 2023. DOI: 10.1530/EJE-22-0931.
DAVIS, S. R. et al. Pharmacokinetics of testosterone topical solutions applied to axilla and upper arm. Clinical Therapeutics, v. 36, n. 3, p. 460-468, 2014. DOI: 10.1016/j.clinthera.2014.01.015.
FDA – Food and Drug Administration. AndroGel® (testosterone gel) label information. Silver Spring: FDA, 2024. Disponível em: https://www.accessdata.fda.gov.
FDA – Food and Drug Administration. Testosterone topical systems and safety communications. Silver Spring: FDA, 2022.
FOOLADI, S. et al. Pharmacokinetics of testosterone cream in postmenopausal women. Menopause, v. 22, n. 7, p. 743-749, 2015. DOI: 10.1097/GME.0000000000000388.
FRONTIERS IN ENDOCRINOLOGY. Testosterone replacement therapy and prostate cancer risk: systematic review and meta-analysis. Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1180241.
FRONTIERS IN PUBLIC HEALTH. Health professionals’ self-prescription practices and risk perception regarding androgen therapy. Frontiers in Public Health, 2023. DOI: 10.3389/fpubh.2023.011489.
HANDELSMAN, D. J. Testosterone therapy: benefits and risks revisited. Nature Reviews Endocrinology, v. 18, p. 415-427, 2022. DOI: 10.1038/s41574-022-00674-0.
IYER, R. S. et al. Pharmacokinetics of testosterone cream applied to the scrotum in hypogonadal men. Andrology, v. 5, n. 4, p. 711-718, 2017. DOI: 10.1111/andr.12357.
JAMA NETWORK. Combined estrogen plus testosterone therapy and breast cancer risk in postmenopausal women. JAMA, v. 295, n. 6, p. 624-630, 2006. DOI: 10.1001/jama.295.6.624.
JAMA NETWORK OPEN. Mendelian randomization of serum testosterone and prostate cancer risk. JAMA Network Open, 2023. DOI: 10.1001/jamanetworkopen.2023.0901.
JCI – Journal of Clinical Investigation. The optimal indication for testosterone replacement therapy in older men. Journal of Clinical Investigation, 2020. DOI: 10.1172/JCI139556.
LEÃO, R. R. Prevalência do uso de testosterona tópica em homens brasileiros. Revista da Associação Médica Brasileira, v. 70, n. 2, p. 201-209, 2024. DOI: 10.1590/1806-9282.2024.0179.
LOPES, A. C. et al. Uso indiscriminado de testosterona e riscos metabólicos. Jornal Brasileiro de Patologia e Medicina Laboratorial, v. 59, n. 2, p. 120-129, 2023. DOI: 10.5935/1676-2444.20230022.
MORGENTALER, A. Androgen therapy and prostate cancer risk: updated review. Urology, v. 180, p. 87-94, 2024. DOI: 10.1016/j.urology.2023.09.004.
MULHALL, J. P. Off-label testosterone use and associated health risks. Andrology, v. 11, n. 1, p. 45-59, 2023. DOI: 10.1111/andr.13328.
NASSAR, A.; SWERDLOFF, R. S. Pharmacokinetics of transdermal testosterone delivery systems. Clinical Pharmacology & Therapeutics, v. 110, n. 3, p. 583-594, 2021. DOI: 10.1002/cpt.2324.
NAVARRO, G. Safety profile of long-term testosterone therapy. The Aging Male, v. 26, n. 1, p. 87-99, 2023. DOI: 10.1080/13685538.2022.2119934.
PMC 8596965. Testosterone use in North America: prescribing trends and cancer risk. National Institutes of Health, 2023. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC8596965/.
PMC 11220914. Testosterone therapy and biochemical recurrence after radical prostatectomy: a multi-institutional cohort study. Prostate Cancer and Prostatic Diseases, 2024. DOI: 10.1038/s41391-024-00918-4.
REVISTA BRASILEIRA DE ENDOCRINOLOGIA E METABOLOGIA. Uso e automedicação de testosterona no Brasil: revisão narrativa crítica. Revista Brasileira de Endocrinologia e Metabologia, v. 68, n. 3, p. 333-349, 2024.
REVISTA BRASILEIRA DE MEDICINA DO ESPORTE. Prevalência de uso de testosterona e anabolizantes em academias brasileiras. Revista Brasileira de Medicina do Esporte, v. 29, n. 1, p. 12-20, 2023. DOI: 10.1590/1517-8692202329012023.
SAAD, F. Topical testosterone formulations: comparative pharmacokinetics and patient preference. Current Opinion in Endocrinology, Diabetes and Obesity, v. 30, n. 2, p. 101-109, 2023. DOI: 10.1097/MED.0000000000000810.
SILVA, M. A.; BARROS, C. R. Absorção cutânea e riscos sistêmicos de testosterona tópica: revisão narrativa. Revista Brasileira de Endocrinologia e Metabologia, v. 68, n. 4, p. 410-422, 2024.
SWERDLOFF, R. S. et al. Transdermal testosterone delivery systems for hypogonadal men. Journal of Clinical Endocrinology & Metabolism, v. 85, n. 12, p. 4500-4510, 2000. DOI: 10.1210/jcem.85.12.7004.
TRAISH, A. M. Testosterone and carcinogenesis: evidence from clinical and experimental studies. Hormone Molecular Biology and Clinical Investigation, v. 52, n. 1, p. 1-15, 2022. DOI: 10.1515/hmbci-2022-0001.
U.S. PHARMACIST. Trends and patterns of testosterone therapy among U.S. males (2018–2022). U.S. Pharmacist, 2022. Disponível em: https://www.uspharmacist.com/article/trends-and-patterns-of-testosterone-therapy-among-us-males.
VIEIRA, P. A. Efeitos adversos cutâneos de hormônios tópicos: revisão sistemática. Anais Brasileiros de Dermatologia, v. 100, n. 2, p. 223-234, 2025. DOI: 10.1016/j.abd.2025.01.007.
